Impact of influenza immunity on the mortality among older adults hospitalized with COVID-19: a retrospective cohort study.
Aged
COVID-19
Influenza Human
Influenza vaccines
Mortality
Journal
Clinical and experimental medicine
ISSN: 1591-9528
Titre abrégé: Clin Exp Med
Pays: Italy
ID NLM: 100973405
Informations de publication
Date de publication:
31 Oct 2023
31 Oct 2023
Historique:
received:
19
05
2023
accepted:
21
09
2023
medline:
31
10
2023
pubmed:
31
10
2023
entrez:
31
10
2023
Statut:
aheadofprint
Résumé
It has been suggested that the outcomes of coronavirus disease 2019 (COVID-19) are better in individuals having recently received an influenza vaccine than in non-vaccinated individuals. We hypothesized that this association depends on the humoral responses against influenza viruses. We aim to assess the relationship between the humoral immunity against influenza and the 3-month all-cause mortality among hospitalized older patients with COVID-19. We performed an exploratory retrospective study of older patients (aged 65 and over) hospitalized for confirmed COVID-19 between November 2020 and June 2021. Previous humoral responses to influenza viruses were assessed using a hemagglutination inhibition assay on routinely collected blood samples. The study's primary outcome was the 3-month all-cause mortality, and the secondary outcomes were severe COVID-19 (oxygen requirement ≥ 6 L/min or ventilatory support) and complications (kidney or heart failure, thrombosis and bacterial infection). In the cohort of 95 patients with COVID-19, immunity against influenza vaccine subtypes/lineages was not significantly associated with 3-month all-cause mortality, with an OR [95%CI] of 0.22 [0.02-1.95] (p = 0.174) for the H1N1pdm09 subtype, 0.21 [0.03-1.24] (p = 0.081) for A/Hong Kong/2671/2019 H3N2 subtype, 1.98 [0.51-8.24] (p = 0.329) for the B/Victoria lineage, and 1.82 [0.40-8.45] (p = 0.437) for the B/Yamagata lineage. Immunity against influenza vaccine subtypes/lineages was also not significantly associated with severity and complication. Immunity against influenza subtypes/lineages included in the 2020-2021 vaccine was not associated with a lower 3-month all-cause mortality among COVID-19 hospitalized patients.Trial registration: The study was approved by a hospital committee with competency for research not requiring approval by an institutional review board (Tours University Medical Center, Tours, France: reference: 2021_015). All patients give the informed consent.
Identifiants
pubmed: 37906387
doi: 10.1007/s10238-023-01203-0
pii: 10.1007/s10238-023-01203-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Our World in Data. Cumulative confirmed COVID-19 cases [Internet]. 2023. https://ourworldindata.org/explorers/coronavirus-data-explorer?zoomToSelection=true&time=2020-03-01..latest&facet=none&uniformYAxis=0&pickerSort=desc&pickerMetric=total_cases&hideControls=true&Metric=Confirmed+cases&Interval=Cumulative&Relative+to+Population=false&Color+by+test+positivity=false&country=~Europe . Accessed August 31, 2023
Our World in Data. Cumulative confirmed COVID-19 deaths. 2023. https://ourworldindata.org/explorers/coronavirus-data-explorer?zoomToSelection=true&time=2020-03-01..latest&facet=none&uniformYAxis=0&pickerSort=desc&pickerMetric=total_cases&hideControls=true&Metric=Confirmed+deaths&Interval=Cumulative&Relative+to+Population=false&Color+by+test+positivity=false&country=~Europe . Accessed August 31, 2023
Chêne G, Bernard-Stoecklin S, Fournier L, Parent du Chatelet I, Savitch Y, Campèse C. Bulletin épidémiologique grippe, semaine 52. Saison 2021–2022. Santé Publique France.. 2022. https://www.santepubliquefrance.fr/content/download/403050/3317612 . Accessed May 30, 2022
Chan CP, Wong NS, Leung CC, Lee SS. Positive impact of measures against COVID-19 on reducing influenza in the Northern Hemisphere. J Travel Med. 2020;27(8):taaa087.
Chow A, Hein AA, Kyaw WM. Unintended Consequence: Influenza plunges with public health response to COVID-19 in Singapore. J Infect. 2020;81(2):e68–9.
doi: 10.1016/j.jinf.2020.04.035
pubmed: 32360879
pmcid: 7192079
Woolbert ME, Spalding CD, Sinaii N, Decker BK, Palmore TN, Henderson DK. Sharp decline in rates of community respiratory viral detection among patients at the National Institutes of Health Clinical Center during the coronavirus disease 2019 (COVID-19) pandemic. Infect Control Hosp Epidemiol. 2023;44(1):62–7.
doi: 10.1017/ice.2022.31
pubmed: 35177161
Konala VM, Adapa S, Gayam V, et al. Co-infection with Influenza A and COVID-19. Eur J Case Rep Intern Med. 2020;7(5): 001656.
pubmed: 32399452
pmcid: 7213830
Abdelrahman Z, Li M, Wang X. Comparative Review of SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza A Respiratory Viruses. Front Immunol. 2020;11: 552909.
doi: 10.3389/fimmu.2020.552909
pubmed: 33013925
pmcid: 7516028
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet Lond Engl. 2020;395(10229):1054–62.
doi: 10.1016/S0140-6736(20)30566-3
Ko JY, Danielson ML, Town M, et al. Risk Factors for Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization: COVID-19-Associated Hospitalization Surveillance Network and Behavioral Risk Factor Surveillance System. Clin Infect Dis Off Publ Infect Dis Soc Am. 2021;72(11):e695-703.
doi: 10.1093/cid/ciaa1419
Casado I, Domínguez A, Toledo D, et al. Effect of influenza vaccination on the prognosis of hospitalized influenza patients. Expert Rev Vaccines. 2016;15(3):425–32.
doi: 10.1586/14760584.2016.1134328
pubmed: 26690376
World Health Organization (2021). Review of global influenza circulation, late 2019 to 2020, and the impact of the COVID-19 pandemic on influenza circulation–WHO European Region, 2005–2019. Weekly Epidemiological Record. 96 (25), 241 - 264. World Health Organization. https://apps.who.int/iris/handle/10665/341995
Krammer F, Smith GJD, Fouchier RAM, et al. Influenza Nat Rev Dis Primer. 2018;4(1):3.
doi: 10.1038/s41572-018-0002-y
SNDS–DCIR- tous régimes–Traitement Santé publique France. Données régionales de couverture vaccinale grippe par saison et dans chaque groupe d’âge (de la saison 2016–2017 à la saison 2022–2023). 2023. https://www.santepubliquefrance.fr/media/files/02-determinants-de-sante/vaccination/sev_2023_tableau_21_cv_grippe_donnees_reg_par_saison_groupe_d’âge_2023 . Accessed May 31, 2023.
Chêne G, Bernard-Stocklen S, Campèse C, Savitch Y. Grippe - Bilan saison 2020–2021. Santé publique France; 2021. https://www.santepubliquefrance.fr/content/download/380880/3183985?version=1 . Accessed May 31, 2023.
Green I, Ashkenazi S, Merzon E, Vinker S, Golan-Cohen A. The association of previous influenza vaccination and coronavirus disease-2019. Hum Vaccines Immunother. 2021;17(7):2169–75.
doi: 10.1080/21645515.2020.1852010
Conlon A, Ashur C, Washer L, Eagle KA, Hofmann Bowman MA. Impact of the influenza vaccine on COVID-19 infection rates and severity. Am J Infect Control. 2021;49(6):694–700.
doi: 10.1016/j.ajic.2021.02.012
pubmed: 33631305
pmcid: 7899024
Wilcox CR, Islam N, Dambha-Miller H. Association between influenza vaccination and hospitalisation or all-cause mortality in people with COVID-19: a retrospective cohort study. BMJ Open Respir Res. 2021;8(1): e000857.
doi: 10.1136/bmjresp-2020-000857
pubmed: 33664123
Zanettini C, Omar M, Dinalankara W, et al. Influenza Vaccination and COVID-19 Mortality in the USA: An Ecological Study. Vaccines. 2021;9(5):427.
doi: 10.3390/vaccines9050427
pubmed: 33923159
pmcid: 8145634
Debisarun PA, Struycken P, Domínguez-Andrés J, et al. The effect of influenza vaccination on trained immunity: impact on COVID-19. Infectious Diseases (except HIV/AIDS); 2020. http://medrxiv.org/lookup/doi/ https://doi.org/10.1101/2020.10.14.20212498 . Accessed April 9, 2022
Lang PO, Govind S, Mitchell WA, Siegrist CA, Aspinall R. Vaccine effectiveness in older individuals: what has been learned from the influenza-vaccine experience. Ageing Res Rev. 2011;10(3):389–95.
doi: 10.1016/j.arr.2010.09.005
Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179-184.
doi: 10.1159/000339789
pubmed: 22890468
Jourdain P, Lefèvre G, Oddoze C, Sapin V, Dievart F, Jondeau G, et al. NT-proBNP en pratique « De la biologie à la clinique ». Ann Cardiol Angéiologie. 2009;58(3):165–79.
doi: 10.1016/j.ancard.2009.03.003
Fried L, Bernardini J, Piraino B. Charlson comorbidity index as a predictor of outcomes in incident peritoneal dialysis patients. Am J Kidney Dis Off J Natl Kidney Found. 2001;37(2):337–42.
doi: 10.1053/ajkd.2001.21300
Katz S, Akpom CA. A measure of primary sociobiological functions. Int J Health Serv Plan Adm Eval. 1976;6(3):493–508.
doi: 10.2190/UURL-2RYU-WRYD-EY3K
Coudeville L, Bailleux F, Riche B, Megas F, Andre P, Ecochard R. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med Res Methodol. 2010;10:18.
doi: 10.1186/1471-2288-10-18
pubmed: 20210985
pmcid: 2851702
Pedersen JC. Hemagglutination-Inhibition Assay for Influenza Virus Subtype Identification and the Detection and Quantitation of Serum Antibodies to Influenza Virus. In: Spackman E, éditeur. Animal Influenza Virus. New York, NY: Springer New York; 2014. p. 11‑25. (Methods in Molecular Biology; vol. 1161). http://link.springer.com/ https://doi.org/10.1007/978-1-4939-0758-8_2 . Accessed April 15, 2022
Trombetta CM, Perini D, Mather S, Temperton N, Montomoli E. Overview of Serological Techniques for Influenza Vaccine Evaluation: Past. Present and Future Vaccines. 2014;2(4):707–34.
pubmed: 26344888
Domnich A, Manini I, Panatto D, Calabrò GE, Montomoli E. Immunogenicity Measures of Influenza Vaccines: A Study of 1164 Registered Clinical Trials. Vaccines. 2020;8(2):E325.
doi: 10.3390/vaccines8020325
Chowdhury MZI, Turin TC. Variable selection strategies and its importance in clinical prediction modelling. Fam Med Community Health. 2020;8(1): e000262.
doi: 10.1136/fmch-2019-000262
pubmed: 32148735
pmcid: 7032893
Van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. J Stat Softw. 2011;45(3):1–67. https://doi.org/10.18637/jss.v045.i0333 .
doi: 10.18637/jss.v045.i0333
Wickham H, Averick M, Bryan J, et al. Welcome to the tidyverse. J Open Source Softw. 2019;4(43):1686.
doi: 10.21105/joss.01686
Harrison E, Drake T, Ots R (2023). finalfit: Quickly Create Elegant Regression Results Tables and Plots when Modelling. R package version 1.0.6, https://github.com/ewenharrison/finalfit .
Mazerolle MJ (2023). AICcmodavg: Model selection and multimodel inference based on (Q)AIC(c). R package version 2.3.2, https://cran.r-project.org/package=AICcmodavg .
Fink G, Orlova-Fink N, Schindler T, et al. Inactivated trivalent influenza vaccination is associated with lower mortality among patients with COVID-19 in Brazil. BMJ Evid-Based Med. 2020; bmjebm-2020–111549.
Sovann LY, Sar B, Kab V, et al. An influenza A (H3N2) virus outbreak in the Kingdom of Cambodia during the COVID-19 pandemic of 2020. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2021;103:352–7.
World Health Organization. Cambodia: WHO Coronavirus Disease (COVID-19) Dashboard With Vaccination Data. 2021. https://covid19.who.int/region/wpro/country/kh . Accessed Sept 18, 2021
Bulut O, Kilic G, Domínguez-Andrés J, Netea MG. Overcoming immune dysfunction in the elderly: trained immunity as a novel approach. Int Immunol. 2020;32(12):741–53.
doi: 10.1093/intimm/dxaa052
pubmed: 32766848
pmcid: 7680842
Chan L, Alizadeh K, Alizadeh K, et al. Review of Influenza Virus Vaccines: The Qualitative Nature of Immune Responses to Infection and Vaccination Is a Critical Consideration. Vaccines. 2021;9(9):979.
doi: 10.3390/vaccines9090979
pubmed: 34579216
pmcid: 8471734
Pawlowski C, Puranik A, Bandi H, et al. Exploratory analysis of immunization records highlights decreased SARS-CoV-2 rates in individuals with recent non-COVID-19 vaccinations. Sci Rep. 2021;11(1):4741.
doi: 10.1038/s41598-021-83641-y
pubmed: 33637783
pmcid: 7910541
Sánchez-Ramón S, Conejero L, Netea MG, Sancho D, Palomares Ó, Subiza JL. Trained Immunity-Based Vaccines: A New Paradigm for the Development of Broad-Spectrum Anti-infectious Formulations. Front Immunol. 2018;9:2936.
doi: 10.3389/fimmu.2018.02936
pubmed: 30619296
pmcid: 6304371
Long BR, Michaelsson J, Loo CP, et al. Elevated frequency of gamma interferon-producing NK cells in healthy adults vaccinated against influenza virus. Clin Vaccine Immunol CVI. 2008;15(1):120–30.
doi: 10.1128/CVI.00357-07
pubmed: 18003818
Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol. 2014;14(1):36–49.
doi: 10.1038/nri3581
pubmed: 24362405
pmcid: 4084561
Ye L, Ohnemus A, Ong LC, et al. Type I and Type III Interferons Differ in Their Adjuvant Activities for Influenza Vaccines. J Virol. 2019;93(23):e01262-e1319.
doi: 10.1128/JVI.01262-19
pubmed: 31511392
pmcid: 6854507
Bastard P, Gervais A, Le Voyer T, et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol. 2021;6(62):eabl4340.
Manry J, Bastard P, Gervais A, et al. The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodies. Proc Natl Acad Sci U S A. 2022 24;119(21):e2200413119.
Allen JC, Toapanta FR, Chen W, Tennant SM. Understanding immunosenescence and its impact on vaccination of older adults. Vaccine. 2020;38(52):8264–72.
doi: 10.1016/j.vaccine.2020.11.002
pubmed: 33229108
pmcid: 7719605
Cunha LL, Perazzio SF, Azzi J, Cravedi P, Riella LV. Remodeling of the Immune Response With Aging: Immunosenescence and Its Potential Impact on COVID-19 Immune Response. Front Immunol. 2020;11:1748.
doi: 10.3389/fimmu.2020.01748
pubmed: 32849623
pmcid: 7427491
Blomaard LC, et al. Frailty is associated with in-hospital mortality in older hospitalised COVID-19 patients in the Netherlands: the COVID-OLD study. Age Ageing. 2021;50(3):631–40. https://doi.org/10.1093/ageing/afab018 .
doi: 10.1093/ageing/afab018
pubmed: 33951156
pmcid: 7929372
Koroleva M, Batarse F, Moritzky S, et al. Heterologous viral protein interactions within licensed seasonal influenza virus vaccines. NPJ Vaccines. 2020;5:3. https://doi.org/10.1038/s41541-019-0153-1 .
doi: 10.1038/s41541-019-0153-1
pubmed: 31934357
pmcid: 6954117